• Type:
  • Category:

BRAIN Biotech AG Financial Results Q1 2023 | Strong Start to Revenue and Cash Improved with CFO

Share

Excerpt

BRAIN Biotech AG, a leading provider of biologization solutions for industries, has reported strong revenue growth in both segments, contributing to a total group revenue increase of 35% and an organic increase of 19% in the first quarter the fiscal year 2022/23.

 

The BioIndustrial segment saw revenue growth of 43.5%, and the BioScience segment’s revenue increased by 10.5% on an organic basis. The company’s cash on hand also improved by €2.4 million to €10.8 million, including the proceeds from the disposal of L.A. Schmitt GmbH.

 

Despite higher personnel and project investments, BRAIN Biotech’s adjusted EBITDA remained profitable. Important events for the quarter included MP Beteiligungs-GmbH expanding its shareholding to approximately 45% and the company reaching project milestones in its collaboration with rare sugars expert Bonumose.

 

Michael Schneiders, CFO, expressed optimism for the rest of the fiscal year, noting the company’s solid growth as a foundation for handling inflationary costs.

BRAIN Biotech AG

Darmstaedter Strasse 34-36
64673 Zwingenberg, Germany

phone +49 6251 9331 86

Chapters

  • Business Highlights 3M 22/23
  • Financial Highlights 3M FY 2022/23
  • Cash & Cash Flow
  • General Risk Factor Update
  • Our Targets

Resources

Host

Michael Schneiders
CFO | BRAIN Biotech AG​

Share

T&C:

This publication is for informational purposes only and should not be considered investment advice. By using this website, you agree to the terms and conditions outlined in the legal pages at www.seat11a.com/legal/

More Company Presentations

More Elevator Pitches

Reviews for BRAIN Biotech AG Financial Results Q1 2023 | Strong Start to Revenue and Cash Improved with CFO

There are currently no reviews for BRAIN Biotech AG Financial Results Q1 2023 | Strong Start to Revenue and Cash Improved with CFO
Scroll to top